Literature DB >> 6344913

Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies.

M Gobbi, F Caligaris-Cappio, G Janossy.   

Abstract

Immunoglobulin heavy chain expression and reactivity of monoclonal antibodies RFA-1, -2, -3, -4 and OKT10 discriminate between majority B lymphocyte populations in the bone marrow and in peripheral lymphoid organs. In this study normal tissues and various B cell malignancies were studied in cell suspensions and tissue sections. Pre-B acute lymphoblastic leukaemia and multiple myeloma apparently reflect the phenotypes on normal B lineage cells of the bone marrow, while centroblastic-centrocytic lymphoma, B chronic lymphoid leukaemia (CLL) and prolymphocytic leukaemia (PLL) show the characteristics of distinct peripheral B lymphoid subsets found at different sites in the lymphoid tissue. These 'normal equivalent' cells are centroblasts and centrocytes in the germinal centre. CLL-like cells at the edge of the germinal centre (a minority population) and strongly Ig positive cells in the lymphocyte corona. Malignant cells in macroglobulinaemia are apparently more closely related to PLL and the corresponding normal peripheral B cells (in the corona) than to myeloma cells or the equivalent normal plasma cells in the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344913     DOI: 10.1111/j.1365-2141.1983.tb02114.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

1.  Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes.

Authors:  T J Kipps; S F Duffy
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry.

Authors:  H G Höffkes; G Schmidtke; M Uppenkamp; U Schmücker
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

3.  Characterization of two distinct antigens expressed on either resting or activated human B cells as defined by monoclonal antibodies.

Authors:  Y Kokai; Y Ishii; K Kikuchi
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

4.  Two monoclonal antibodies raised against a Burkitt lymphoma cell line recognise different cell types within lymphoid follicles.

Authors:  L J Murray; S Dhut; L C Walker; M Rainey; J A Habeshaw
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

5.  CD5-positive B cells after T cell depleted bone marrow transplantation.

Authors:  H G Drexler; M K Brenner; J Z Wimperis; S M Gignac; G Janossy; H G Prentice; A V Hoffbrand
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

6.  Human tonsil B lymphocyte function. I. The proliferative response to Staphylococcus aureus and pokeweed mitogen in relation to surface heavy chains mu and delta.

Authors:  G C Mudde; C J Verberne; K Groeneveld; G C De Gast
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

7.  Immunophenotyping of B lymphocytes by multiparametric flow cytometry in bone marrow aspirates of healthy adults.

Authors:  H G Höffkes; G Schmidtke; U Schmücker; M Uppenkamp; G Brittinger
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

8.  Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen.

Authors:  M Gobbi; F Caligaris-Cappio; D Campana; P L Tazzari; L Bergui; M Cavo; S Tura
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

9.  Reactivity of Leu 1 and T101 monoclonal antibodies with B cell lymphomas (correlations with other immunological markers).

Authors:  T Al Saati; G Laurent; P Caveriviere; F Rigal; G Delsol
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

10.  Membrane phenotypic studies in B cell lymphoproliferative disorders.

Authors:  C S Scott; H J Limbert; I D MacKarill; B E Roberts
Journal:  J Clin Pathol       Date:  1985-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.